| Ocrelizumab versus Interferon Beta 1a in Relapsing Multiple Sclerosis SL Hauser, A Bar-Or, G Comi N Engl J Med 376, 221 - 234, 0 | 2028* | |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1081 | 2018 |
| Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States G Kobelt, J Berg, D Atherly, O Hadjimichael Neurology 66 (11), 1696-1702, 2006 | 464* | 2006 |
| Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses I Kleiter, A Gahlen, N Borisow, K Fischer, KD Wernecke, B Wegner, ... Annals of neurology 79 (2), 206-216, 2016 | 438 | 2016 |
| Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures S Jarius, F Paul, D Franciotta, K Ruprecht, M Ringelstein, R Bergamaschi, ... Journal of the neurological sciences 306 (1-2), 82-90, 2011 | 403 | 2011 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 297 | 2017 |
| Animal models of multiple sclerosis—potentials and limitations E Mix, H Meyer-Rienecker, HP Hartung, UK Zettl Progress in neurobiology 92 (3), 386-404, 2010 | 287 | 2010 |
| Disease-modifying therapies and infectious risks in multiple sclerosis A Winkelmann, M Loebermann, EC Reisinger, HP Hartung, UK Zettl Nature Reviews Neurology 12 (4), 217-233, 2016 | 282 | 2016 |
| Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) HP Tony, G Burmester, H Schulze-Koops, M Grunke, J Henes, I Kötter, ... Arthritis research & therapy 13, 1-14, 2011 | 257 | 2011 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 249 | 2017 |
| Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions I Kleiter, A Gahlen, N Borisow, K Fischer, KD Wernecke, K Hellwig, ... Neurology: Neuroimmunology & Neuroinflammation 5 (6), e504, 2018 | 225 | 2018 |
| The cerebrospinal fluid in multiple sclerosis F Deisenhammer, H Zetterberg, B Fitzner, UK Zettl Frontiers in immunology 10, 726, 2019 | 220 | 2019 |
| Longitudinal extensive transverse myelitis—it's not all neuromyelitis optica C Trebst, P Raab, EV Voss, P Rommer, M Abu-Mugheisib, UK Zettl, ... Nature Reviews Neurology 7 (12), 688-698, 2011 | 196 | 2011 |
| T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy J Schmidt, R Gold, L Schönrock, UK Zettl, HP Hartung, KV Toyka Brain 123 (7), 1431-1441, 2000 | 178 | 2000 |
| Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity P Flachenecker, T Henze, UK Zettl European neurology 71 (5-6), 271-279, 2014 | 177 | 2014 |
| CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of … A Dudesek, F Rimmele, S Tesar, S Kolbaske, PS Rommer, R Benecke, ... Clinical & Experimental Immunology 175 (3), 385-396, 2014 | 173 | 2014 |
| Multiple sclerosis and fatigue: a review on the contribution of inflammation and immune-mediated neurodegeneration R Patejdl, IK Penner, TK Noack, UK Zettl Autoimmunity reviews 15 (3), 210-220, 2016 | 171 | 2016 |
| Cognitive impairment in multiple sclerosis A Winkelmann, C Engel, A Apel, UK Zettl Journal of neurology 254, II35-II42, 2007 | 171 | 2007 |
| Neuroimaging in stroke recovery: a position paper from the First International Workshop on Neuroimaging and Stroke Recovery H Christensen, L Derex, JB Pialat, M Wiart, N Nighoghossian, M Hermier, ... Cerebrovascular diseases 18 (3), 260-267, 2004 | 171 | 2004 |
| Macrophages in multiple sclerosis W Brück, N Sommermeier, M Bergmann, U Zettl, HH Goebel, ... Immunobiology 195 (4-5), 588-600, 1996 | 168 | 1996 |
